Sage Therapeutics/SAGE

$21.93

0.32%
-
1D1W1MYTD1YMAX

About Sage Therapeutics

Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed the two FDA-approved treatments indicated for postpartum depression and is advancing a robust pipeline to target unmet needs in brain health. The Company is targeting diseases and disorders of the brain across its clinical development and earlier stage pipeline. Its product ZURZUVAE is for the treatment of postpartum depression (PPD) in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABA receptors, targeting both synaptic and extra synaptic GABA receptors. Its product ZULRESSO (brexanolone) CIV injection is for the treatment of PPD in individuals 15 years old and older. It is also developing a portfolio of other novel compounds that target GABA receptors, including SAGE-324, which is a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing. Its second area of focus for development is novel compounds that target the NMDA receptor.

Ticker

SAGE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Barry Greene

Employees

487

Headquarters

Cambridge, United States

SAGE Metrics

BasicAdvanced
$1.31B
Market cap
-
P/E ratio
-$9.05
EPS
0.87
Beta
-
Dividend rate

What the Analysts think about SAGE

Analyst Ratings

Majority rating from 22 analysts.
Hold

Price Targets

Average projection from 18 analysts.
25.4% upside
High $70.00
Low $18.00
$21.93
Current price
$27.50
Average price target

SAGE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-41.97% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$77.9M
2,785.19%
Net income
$-32.7M
-83.78%
Profit margin
-41.97%
-99.44%

SAGE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 56.94%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$2.46
-$2.68
-$3.37
-$0.55
-
Expected
-$2.50
-$2.55
-$2.73
-$1.28
-$1.60
Surprise
-1.44%
4.95%
23.42%
-56.94%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Sage Therapeutics stock

Buy or sell Sage Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing